A Study of TAS-120 in Patients With Metastatic Breast Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- FGFR2 Amplification
- Metastatic Breast Cancer
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Up to approximately 168 patients will be enrolled among the 4 cohorts as outlined below: Cohort 1 - HR+ HER2- Measurable Disease w/ FGFR2 Amplification Cohort 2 - TNBC Measurable Disease w/ FGFR2 Amplification Cohort 3 - HR+ HER2- or TNBC Non-Measurable Disease w/ FGFR2 Amplification Cohort 4 - HR+ ...
Up to approximately 168 patients will be enrolled among the 4 cohorts as outlined below: Cohort 1 - HR+ HER2- Measurable Disease w/ FGFR2 Amplification Cohort 2 - TNBC Measurable Disease w/ FGFR2 Amplification Cohort 3 - HR+ HER2- or TNBC Non-Measurable Disease w/ FGFR2 Amplification Cohort 4 - HR+ HER2- Measurable Disease w/ FGFR1 Amplification
Tracking Information
- NCT #
- NCT04024436
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon